Product Images Dabigatran Etexilate

The text mentions the details of a medicine named Dabigatran Etexilate, which is available in the form of 150 mg capsules. The packaging has been carried out by American Health Packaging located in Columbus, Ohio, with a specific lot number and expiry date mentioned on the packaging. The output has some typos, but the necessary information is present in the text.*

This is a prescription drug called Dabigatran Etexilate, available in capsule form. The package contains 20 capsules divided into 5 packs of 4 each. Each capsule contains 7295mg of dabigatran ctexials mesylate, equivalent to 150mg of dabigatran etexilate. Dosage information is available in the package insert. The pharmacist should dispense the medication guide along with the capsules to the patient. The capsules should be stored in the original blister to protect from moisture and kept away from children. The manufacturer is Camber Pharmaceuticals, and it is distributed by American Health Packaging in Columbus, Ohio.*

This is a medication package for Dabigatran Etexilate capsules. Each capsule contains 85.48 mg dabigatran oxalate mesylate equivalent to 75 mg of dabigatian etexiate. The recommended dosage and storage information are included in the package insert. The medication should be kept in its original packaging to protect it from moisture, and must be used within 4 months if taken out of the packaging. This medication shouldn't be used if the package is torn or broken. The distributor of this medication is American Health Packaging, Columbus, Ohio.*

The text appears to be a table that reports the pharmacokinetic measurements of several drugs with respect to their interactions and time differences. The drugs mentioned are Dronedarone, Ketoconazole, Amiodarone, Clasithromycin, Quinidine, Ticagrelor, Verapamil, and Rifampicin. The table also displays values of fold change and 90% CI for the drugs. No further information is available to provide a useful description.*

This is a list of drugs and their effects on Cmax (maximum concentration of a drug in the bloodstream) and AUC (area under the curve, a measure of the total amount of a drug in the bloodstream over time). The drugs include atorvastatin, clopidogrel, diclofenac, digoxin, enoxaparin, pantoprazole, and ranitidine. The table shows the fold change (ratio of the drug's effect compared to a reference) and 90% CT (confidence interval for the effect). There is no more information available in the text.*

The text contains statistical data on major bleeding events in patients using Dabigatran 150 and Warfarin. the data shows a comparison of patients using VKA and those who were naive or experienced. The data also shows a comparison of patients based on their age, gender, weight, history of stroke/TIA, diabetes, CHADS? Score, CrCL, region, and Asa use at baseline. The text is most likely a report from a clinical trial study evaluating the safety of Dabigatran 150 and Warfarin in patients with different characteristics.*

This appears to be a chart or graph related to the time course of aPTT (activated partial thromboplastin time) for a medication called dabigatran etexilate capsules. The chart includes dosing instructions based on a patient's creatinine clearance (CrCl) level. The recommended dose is 150mg twice daily for patients with a CrCl greater than 30 mL/min and 75mg twice daily for patients with a CrCl less than 30 mL/min. The x-axis appears to represent time in hours with data points at 0, 24, 48, 72, and 96 hours.*

The text provided is a chart or table, and it displays the "Estimated cumulative probability" based on time (in months) and medication type. The medication types listed in the chart are DE 110mg bid, DE 150mg bid, and Warfarin, and the subjects at risk are listed for each medication type by time from randomization.*